Report Title:
PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025 Published On: February 2017
Category: Life Sciences
Pages: 403
Report Overview: PharmaPoint: Rheumatoid Arthritis Global Drug Forecast and Market Analysis to 2025 Summary Rheumatoid arthritis RA is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over six million individuals in the 8MM covered in this report US, France, Germany, Italy, Spain, UK, Japan, and Australia and this prevalence is expected to grow to just shy of 7 million individuals by 2025. The antiTNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2015 and 2025. With the antiTNFs as extremely effective for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars launch across the 8MM and begin to gain traction in these markets. Scope Overview of rheumatoid arthritis RA, including etiology, pathophysiology, and countryspecific diagnosis and treatment recommendations. Annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the RA biologics and biosimilars markets. Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically JAK inhibitors such as Eli Lilly/Incyte’s Olumiant baricitinib, novel biologics such as AstraZenecaMedImmune’s mavrilimumab, and biosimilars such as Celltrion/Hospira/Pfizer’s Inflectra/Remsima, Samsung Bioepis/Biogen/Merck’s Flixabi and Benepali, Sandoz’s Erelzi, and Amgen’s Amjevita. Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is
24marketreports | International +1 646 781 7170 | www.24marketreports.com
independently researched to provide qualitative analysis of its implications. Reasons to buy The report will enable you to Develop and design your inlicensing and outlicensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the RA market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage. Track drug sales in the eight major RA markets from 20152025. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents: 1 Table of Contents 1 Table of Contents 10 1.1 List of Tables 16 1.2 List of Figures 23 2 Introduction 25 2.1 Catalyst 25 2.2 Related Reports 25 2.3 Upcoming Related Reports 26 3 Disease Overview 27 3.1 Etiology and Pathophysiology 27 3.1.1 Etiology 27 3.1.2 Pathophysiology 27 3.2 Symptoms 32 3.3 Prognosis 32 3.4 Quality of Life 33 4 Epidemiology 34 4.1 Disease Background 34 4.2 Risk Factors and Comorbidities 35 4.3 Global Trends 36 4.3.1 Diagnosed Incidence 37 4.3.2 Prevalence 39
24marketreports | International +1 646 781 7170 | www.24marketreports.com
4.4 Forecast Methodology 41 4.4.1 Sources Used 41 4.4.2 Forecast Assumptions and Methods 45 4.4.3 Sources Not Used 55 4.5 Epidemiological Forecast for RA 20152025 55 4.5.1 Diagnosed Incident Cases 55 4.5.2 Diagnosed Prevalent Cases 62 4.5.3 Total Prevalent Cases 70 4.6 Discussion 77 4.6.1 Epidemiological Forecast Insight 77 4.6.2 Limitations of the Analysis 78 4.6.3 Strengths of the Analysis 79 5 Disease Management 80 5.1 Diagnosis and Treatment Overview 80 5.1.1 Diagnosis 80 5.1.2 Treatment Guidelines 82 5.1.3 Leading Prescribed Drugs for the Treatment of RA 92 5.1.4 Clinical Practice 93 5.2 US 94 5.3 France 97 5.4 Germany 99 5.5 Italy 102 5.6 Spain 104 5.7 UK 106 5.8 Japan 108 5.9 Australia 110 6 Competitive Assessment 112 6.1 Overview 112 6.2 Product Profiles Major Brands 113 6.2.1 Enbrel etanercept 113 6.2.2 Humira adalimumab 119 6.2.3 Remicade infliximab 123 6.2.4 Simponi golimumab 129 6.2.5 Cimzia certolizumab pegol 134 6.2.6 Orencia abatacept 139 6.2.7 Actemra/RoActemra tocilizumab 145 6.2.8 Rituxan/MabThera rituximab 150 6.2.9 Inflectra/Remsima infliximab biosimilar 155 6.2.10 Flixabi infliximab biosimilar 158 6.2.11 Benepali etanercept biosimilar 161 6.2.12 Erelzi etanercept biosimilar 164 6.2.13 Amjevita adalimumab biosimilar 167 6.2.14 Xeljanz tofacitinib 169 6.2.15 Iguratimod/T614 175 6.2.16 Methotrexate Numerous Brands 178 6.3 Biosimilars Assessment 180
24marketreports | International +1 646 781 7170 | www.24marketreports.com
6.3.1 Introduction 180 6.3.2 Biosimilars in the Immunology Community 182 6.3.3 By the Numbers: Biosimilars in Development 182 6.3.4 The Impact of Biosimilars Is Being Felt Throughout the Pharmaceutical Industry 187 6.3.5 Uptake of Biosimilars for RA Is Expected to Vary by Market 188 6.4 Other Therapies 192 7 Unmet Needs and Opportunities 193 7.1 Overview 193 7.2 Development of CostEffective Therapies 194 7.2.1 Unmet Need 194 7.2.2 Gap Analysis 195 7.2.3 Opportunity 195 7.3 Biomarkers to Predict Responsiveness to Therapy 196 7.3.1 Unmet Need 196 7.3.2 Gap Analysis 197 7.3.3 Opportunity 198 7.4 Early Diagnosis of RA 198 7.4.1 Unmet Need 198 7.4.2 Gap Analysis 199 7.4.3 Opportunity 199 7.5 Personalized Treatment Approach 200 7.5.1 Unmet Need 200 7.5.2 Gap Analysis 200 7.5.3 Opportunity 202 8 Pipeline Assessment 204 8.1 Overview 204 8.2 Clinical Trial Mapping 204 8.2.1 Clinical Trials by Class 204 8.3 Promising Drugs in Clinical Development 205 8.3.1 Sarilumab 209 8.3.2 Sirukumab 218 8.3.3 Clazakizumab 224 8.3.4 Vobarilizumab ALX0016 231 8.3.5 Mavrilimumab 236 8.3.6 Pralia denosumab 242 8.3.7 Olumiant baricitinib 247 8.3.8 Peficitinib 255 8.3.9 Filgotinib 261 8.3.10 Upadacitinib 269 8.3.11 Piclidenoson 275 8.4 Other Drugs in Development 279 9 Current and Future Players 281 9.1 Trends in Corporate Strategy 284 9.2 Company Profiles 285 9.2.1 AbbVie 285 9.2.2 Pfizer 287
24marketreports | International +1 646 781 7170 | www.24marketreports.com
9.2.3 Amgen 289 9.2.4 Johnson & Johnson 292 9.2.5 Eli Lilly 294 9.2.6 BristolMyers Squibb 295 9.2.7 UCB 297 9.2.8 Roche 299 9.2.9 GlaxoSmithKline 301 9.2.10 Sanofi 302 9.2.11 AstraZeneca MedImmune 304 9.2.12 Astellas 306 9.2.13 Daiichi Sankyo 308 9.2.14 Samsung Bioepis 310 9.2.15 Sandoz 312 10 Market Outlook 315 10.1 Global Markets 315 10.1.1 Forecast 315 10.1.2 Drivers and Barriers Global Issues 319 10.2 US 322 10.2.1 Forecast 322 10.2.2 Key Events 325 10.2.3 Drivers and Barriers 325 10.3 5EU 328 10.3.1 Forecast 328 10.3.2 Key Events 331 10.3.3 Drivers and Barriers 332 10.4 Japan 334 10.4.1 Forecast 334 10.4.2 Key Events 337 10.4.3 Drivers and Barriers 338 10.5 Australia 341 10.5.1 Forecast 341 10.5.2 Key Events 343 10.5.3 Drivers and Barriers 344 11 Appendix 346 11.1 Bibliography 346 11.2 Abbreviations 372 11.3 Methodology 378 11.4 Forecasting Methodology 378 11.4.1 Diagnosed RA Patients 378 11.4.2 Percentage of DrugTreated Patients 379 11.4.3 Drugs Included in Each Therapeutic Class 379 11.4.4 Launch and Patent Expiry Dates 380 11.4.5 General Pricing Assumptions 381 11.4.6 Individual Drug Assumptions 382 11.4.7 Generic and Biosimilar Erosion 393 11.4.8 Pricing of Pipeline Agents 393
24marketreports | International +1 646 781 7170 | www.24marketreports.com
11.5 Primary Research KOLs Interviewed for This Report 396 11.6 Primary Research Prescriber Survey 398 11.7 About the Authors 399 11.7.1 Analyst 399 11.7.2 Therapy Area Director 399 11.7.3 Epidemiologist 399 11.7.4 Global Director of Therapy Analysis and Epidemiology 401 11.8 About GlobalData 402 11.9 Disclaimer 402
Get More Information about the Report: Report URL: https://www.24marketreports.com/life-sciences/pharmapoint-rheumatoid-arthritis---global-drug -forecast-and-market-analysis-to-2025 To get Report Sample: https://www.24marketreports.com/request-sample/pharmapoint-rheumatoid-arthritis---global-d rug-forecast-and-market-analysis-to-2025
24marketreports | International +1 646 781 7170 | www.24marketreports.com